- Home
- BTOG vs ITRM Comparison
BTOG vs ITRM Comparison
Compare BTOG & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTOG | ITRM |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Singapore | Ireland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 24.3M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BTOG | ITRM |
|---|---|---|
| Price | $0.27 | $0.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $39,495.00 | ★ $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $325.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.12 | $0.36 |
| 52 Week High | $1.48 | $3.02 |
Technical Indicators
Market Signals| Indicator | BTOG | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 44.83 | 45.29 |
| Support Level | $0.25 | $0.40 |
| Resistance Level | $0.28 | $0.50 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 84.62 | 58.91 |
Price Performance
Historical ComparisonAbout BTOG Bit Origin Limited
Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions. It derives all of its revenue from Bitcoin mining.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.